Epcoritamab

Summary

Epcoritamab (CHEMBL4650393) is an approved antibody (ATC L01FX27) targeting MS4A1 and CD3E; indicated across 8 conditions including diffuse large b-cell lymphoma and neoplasm of mature b-cells.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: L01FX27
• Targets: 2 (MS4A1, CD3E)
• Indications: 8 conditions
• Clinical trials: 53

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650393
Name	Epcoritamab
Type	Antibody
Max phase	4
ATC	L01FX27

Also known as: Epcoritamab, Epcoritamab-bysp, Epkinly, GEN-3013, GEN3013, Tepkinly, EPCORITAMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
MS4A1	CD20 (membrane-spanning 4-domains, subfamily A, member 1)	Binding		0%	P11836
CD3E	CD3e	Binding		0%	P07766

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 2 target gene(s): MS4A1, CD3E.

Top Reactome pathways

10 total, by targets touching each:

Pathway	Targets	Genes
Adaptive Immune System	1	CD3E
Immune System	1	CD3E
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	1	CD3E
TCR signaling	1	CD3E
Downstream TCR signaling	1	CD3E
Phosphorylation of CD3 and TCR zeta chains	1	CD3E
Translocation of ZAP-70 to Immunological synapse	1	CD3E
Generation of second messenger molecules	1	CD3E
Regulation of T cell activation by CD28 family	1	CD3E
Co-inhibition by PD-1	1	CD3E

Dominant GO biological processes

GO term	Targets
cell surface receptor signaling pathway	2
store-operated calcium entry	1
humoral immune response	1
response to bacterium	1
B cell differentiation	1
B cell proliferation	1
B cell activation	1
B cell receptor signaling pathway	1
protein tetramerization	1
calcium ion import into cytosol	1
positive regulation of calcium ion import across plasma membrane	1
positive regulation of cell-matrix adhesion	1
adaptive immune response	1
positive regulation of T cell anergy	1
T cell anergy	1

Indications & clinical

Indications

8 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
diffuse large B-cell lymphoma	4	MONDO:0018905	EFO:0000403
neoplasm of mature B-cells	4	MONDO:0004949	EFO:0000096
follicular lymphoma	4	MONDO:0018906	MONDO:0018906
neoplasm	4	MONDO:0005070	EFO:0000616
non-Hodgkin lymphoma	2	MONDO:0018908	EFO:0005952
B-cell chronic lymphocytic leukemia	1	MONDO:0004948	EFO:0000095
mantle cell lymphoma	1	MONDO:0018876	EFO:1001469
B-cell non-Hodgkin lymphoma	1	MONDO:0015759	EFO:1001938

Clinical trials

Total trials: 53.

Phase distribution

Phase	Trials
PHASE2	31
PHASE1/PHASE2	8
PHASE3	6
PHASE1	6
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04628494	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
NCT05409066	PHASE3	ACTIVE_NOT_RECRUITING	Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
NCT05578976	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT06191744	PHASE3	RECRUITING	Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06508658	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT07226752	PHASE3	ACTIVE_NOT_RECRUITING	A Sub-study Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
NCT03625037	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
NCT04542824	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
NCT04623541	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter’s Syndrome
NCT04663347	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
NCT05201248	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
NCT05283720	PHASE2	RECRUITING	A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
NCT05451810	PHASE2	ACTIVE_NOT_RECRUITING	A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
NCT05660967	PHASE2	ACTIVE_NOT_RECRUITING	Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
NCT05783609	PHASE2	RECRUITING	Epcoritamab and Rituximab for First-line Follicular Lymphoma
NCT05791409	PHASE1/PHASE2	RECRUITING	Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
NCT05848765	PHASE2	RECRUITING	Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
NCT05852717	PHASE2	RECRUITING	Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
NCT06045247	PHASE2	RECRUITING	Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
NCT06112847	PHASE2	ACTIVE_NOT_RECRUITING	Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma
NCT06238648	PHASE2	RECRUITING	Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
NCT06287398	PHASE2	RECRUITING	Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
NCT06414148	PHASE2	RECRUITING	MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma
NCT06458439	PHASE2	RECRUITING	Epcoritamab-CAR T Cells for Large B-cell Lymphomas
NCT06510361	PHASE2	RECRUITING	Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
NCT06510491	PHASE2	RECRUITING	Epcoritamab in Previously Treated WM
NCT06536049	PHASE1/PHASE2	RECRUITING	Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
NCT06563596	PHASE2	RECRUITING	Epco, Zanu, Ritux for R/R FL or MZL
NCT06723457	PHASE2	ACTIVE_NOT_RECRUITING	Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
NCT06796998	PHASE2	RECRUITING	Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
NCT06811272	PHASE2	RECRUITING	Outpatient Epcoritamab as 2L in NTE R/R DLBCL
NCT06905509	PHASE2	RECRUITING	Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
NCT06919939	PHASE2	RECRUITING	Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
NCT06931652	PHASE2	RECRUITING	Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab
NCT07097363	PHASE2	RECRUITING	Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
NCT07108998	PHASE2	RECRUITING	Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
NCT07126236	PHASE2	RECRUITING	Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma
NCT07197307	PHASE2	NOT_YET_RECRUITING	Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT07218510	PHASE2	RECRUITING	Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
NCT07365306	PHASE2	RECRUITING	Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).